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ABSTRACT
Introduction Auditory verbal hallucinations (AVHs) 
are associated with distress and reduced functioning. 
Research suggests that distress is associated with 
the voice hearer’s responding to AVH in a passive and 
subordinate manner. A novel approach focuses on relating 
to AVH and teaches assertive responses to AVH using 
experiential role- plays. A small pilot study found a large 
effect of this approach on AVH distress but an independent 
multicentre study is required to ascertain effectiveness 
across different settings. We aim to estimate the expected 
effect for a subsequent trial to demonstrate that adding 
a module of Relating Therapy (RT) to treatment as usual 
(TAU) is superior to TAU alone in reducing AVH distress. 
We also test the feasibility of patient recruitment, therapist 
training, and therapy monitoring in different psychological 
and psychiatric outpatient facilities in Germany.
Methods and analysis We will recruit 75 patients 
diagnosed with a schizophrenia spectrum disorder and 
persistent distressing AVH across four sites. Patients will 
be randomised to receive either 16 sessions of RT plus 
TAU or TAU alone within a 5- month period. Randomisation 
will be stratified by sites. Single- blind assessments will 
take place at baseline, at 5 months (T1) and at 9 months 
(T2). The primary outcome is the distress factor score of 
the AVH subscale of the Psychotic Symptoms Rating Scale 
at T2 adjusted for the baseline value. Secondary outcomes 
are change in depressive symptoms, quality of life, time 
spent in structured activities as well as negative relating to 
voices and to other people.
Ethics and dissemination The trial has received ethical 
approval from the German Psychological Society Ethics 
Committee. The trial results will be disseminated through 
conference presentations, peer- reviewed publications and 
social media.




Despite its comparatively low prevalence, 
schizophrenia is listed as the eighth leading 
cause of disability- adjusted life years world-
wide in the age group 15–44 years in the 
World Health Report 2001.1 Thus, devel-
oping effective and enduring treatments 
for schizophrenia spectrum disorders and 
facilitating recovery of patients are a crucial 
challenge. Many researchers suggest that 
treatments for severe mental disorders are 
most likely to be improved by focusing on 
clearly defined single symptoms.2 3
Auditory verbal hallucinations (AVHs) 
are a sensory experience in the absence of 
external stimulation of the sensory organ. 
AVHs typically involve hearing voices that vary 
in length, complexity and content (eg, benev-
olent or malevolent, critical, commenting or 
commanding). With a prevalence of about 
60%–70%, AVHs are common in psychotic 
disorders4–6 and are associated with high 
levels of distress,7 8 reduced occupational 
and social functioning,8 9 and an increased 
risk of suicidal behaviour.10 In particular, 
the distress related to AVH is linked to func-
tional impairment and harm to self and 
others.11 12 It is therefore not surprising that 
patients with persistent AVH report the reduc-
tion of distress to be a priority for treatment.13 
In a survey by the International Consortium 
of Hallucinations Research, 93% of the 
participants rated AVH- related distress reduc-
tion among their top three most important 
Strengths and limitations of this study
 ► Prospective multicentre pilot study.
 ► Randomised controlled, single- blind study design.
 ► Patients cannot be blinded to the treatment alloca-
tion, which could introduce bias into the data.
 ► The two- armed study design lacks a third compara-
tor that directly targets auditory verbal hallucination 
distress.
 ► Due to the lack of German- speaking therapists with 
experience in conducting Relating Therapy who 
could serve as independent experts, the adherence 
checks will be done by the supervisor (MH) based on 
translations of the recorded therapy sessions.
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therapeutic outcomes over and above social and occupa-
tional recovery or general well- being.14
AVHs in the context of psychotic disorders are gener-
ally treated with antipsychotic medication as a first line 
of treatment (and in many cases the only line).15 Clinical 
drug trials typically report small to moderate effects for 
psychotic symptoms in general and reanalyses of these 
trials indicate that these effects can be generalised to 
AVH.16 Nevertheless, about one- third of the patients who 
take antipsychotics continue to have AVH.17 Also, medica-
tion is often not taken as prescribed10 and bears the risk of 
severe adverse effects, including metabolic and cardiovas-
cular problems.18 Finally, there is a growing concern over 
the cumulative effects of long- term use of antipsychotics 
on physical health and brain structure.19 This underlines 
the necessity to develop safer treatments that are more 
readily accepted by patients.
Psychological interventions for AVH are mostly a form 
of cognitive–behavioural therapy for psychosis (CBTp) 
and typically include enhancing coping strategies and/
or changing beliefs about AVH. Meta- analyses confirm a 
small effect of CBTp on psychotic symptoms in general.20 
There is also evidence of an effect of CBTp in terms of 
reducing AVH20 21 as a secondary outcome, however these 
effects are small and diminish at follow- up assessments.20 
There have been several recent attempts to improve 
outcomes by taking a symptom- focused approach to AVH 
(ie, the COMMAND22 and Avatar Therapy23 trials), but 
these either do not show an effect on AVH distress,22 
the outcome prioritised by patients, or this effect was no 
longer superior to the control group at follow- up.23
Novel targeted interventions may be more successful 
in reducing AVH distress if they specifically target those 
mechanisms that are causing the distress. One likely 
mechanism causing AVH- related distress stems from 
the relationship people have with their AVH. Previous 
research shows patients to have subordinating and intru-
sive relationships with their AVH. These relationships 
share similarities with patients’ relationships with people 
within their social environments24 25 and empirical find-
ings suggest that hearers have ‘integrated, personally 
coherent relationships with their AVH26 that are likely 
to be imbued with the complexity of social relationships. 
The intervention to be evaluated in this trial builds on 
these findings and on an interpersonal theory of relating 
by Birtchnell.27 The application of this theory to the expe-
rience of AVH has suggested that AVH distress is associ-
ated with the hearer’s perception that AVHs relate to 
them negatively in a dominant and intrusive manner, and 
with the hearer relating negatively in a distant and passive 
manner.24 25 28 The Relating Therapy (RT) approach aims 
to reduce negative relating in order to reduce AVH distress. 
RT has been tested in a pilot randomised controlled trial 
(RCT) that compared RT+TAU (treatment as usual) with 
TAU and included 29 patients with distressing AVH in the 
UK.29 This study established that it is possible to recruit 
and retain patients (87% remained in the trial by the 
5- month follow- up). After 4 months, 50% in the RT+TAU 
group and 13% in the TAU group had shown a clinically 
important decrease on the primary outcome; 5 months 
later these numbers were 43% and 13%, respectively 
(estimated effect size for follow- up of d=1.4). If this effect 
can be confirmed in independent multicentre trials, RT 
could be incorporated into different healthcare formats 
and have a positive impact on the well- being and recovery 
of patients with AVH.
Objectives
Although the UK pilot trial on the RT approach29 produced 
a large effect on AVH distress, the trial was neither suffi-
ciently powered nor set up to show that effects can be 
generalised across a variety of settings that will differ in 
terms of therapist training and in what constitutes TAU. 
Thus, an adequately powered multicentre trial is needed 
to demonstrate that the effects on distress are reliable 
and can be generalised across different settings. Prior to 
conducting a large- scale cost- intensive multicentre trial 
within the German healthcare setting, it is necessary to 
first establish in a feasibility study that:
1. the effect found in the small pilot trial can be repli-
cated in German outpatient settings by training and 
supervising therapists. The question at issue here is 
whether the German translation of the therapy manu-
al, the therapist training and the planned supervision 
are sufficient to deliver the RT module at a satisfactory 
standard and whether the patients are equally likely 
to complete and benefit from the intervention as they 
were in the UK setting, in which the initial pilot trial 
was conducted;
2. the trial infrastructure can be implemented, and a suf-
ficient number of suitable patients can be recruited 
within German outpatient settings. Relevant settings 
for the future delivery of RT are practices of licensed 
psychologists and psychiatrists and outpatient wards of 
psychiatric clinics. For the purpose of the study, out-
patient facilities situated at the university psychology 
departments and outpatient wards of university clinics 
that provide a research infrastructure for clinical trials 
will serve as proxies for these two types of settings.
The feasibility study will also inform our understanding 
of what constitutes TAU for this population within the 
selected settings, which will be used for a protocol of an 
optimised and more standardised TAU in a future definite 
RCT. The recruitment rates in the centres will provide 
a basis on which to establish the required number of 
centres. Moreover, we aim to establish a realistic estimate 
of trial and follow- up completion rates across all types of 
centres. Finally, the effect size from this feasibility trial will 
provide a more accurate basis for the power calculation.
Trial design
This is a feasibility study for a subsequent fully powered 
single- blind, prospective, randomised, controlled, 
parallel- group, two- armed, multicentre, open trial to 
demonstrate that adding an RT module to TAU is supe-
rior to TAU alone in reducing AVH distress. The primary 
3Lincoln TM, et al. BMJ Open 2021;11:e046390. doi:10.1136/bmjopen-2020-046390
Open access
efficacy aim is to show that the mean distress factor score 
of the PSYRATS- AVH30 31 (Psychotic Symptoms Rating 
Scale–Auditory Hallucination Subscale) at 9 months (T2) 
adjusted for the baseline value is lower in the intervention 
than in the control group.
Feasibility questions will relate to patient recruitment, 
therapist training and therapy monitoring in different 
types of psychological and psychiatric outpatient facilities.
The results will be used to plan the design for a future 
trial within the German healthcare system.
METHODS: PARTICIPANTS, INTERVENTIONS AND OUTCOMES
Patient and public involvement
The EmPeeRie (Empower Peers to Research) Network at 
the university clinic in Hamburg and the Psychosis Lived 
Experience Group (UK patient involvement group led 
by Mark Hayward) were involved in discussing the mini-
mally relevant assumed treatment effect in the primary 
outcome measure. The EmPeeRie group also provided 
advice on how to recruit participants in patient networks.
The EmPeeRie group will consult on issues concerning 
informed consent, participant well- being, recruitment 
and retention, interpretation of findings and dissemi-
nation. This involvement will take place in the form of 
regular group meetings. An ‘involvement log’ will be kept 
to record and track the influence of the advice offered by 
EmPeeRie.
Finally, a person from this group with lived experience 
of AVH has consented to be a member of the Data Safety 
and Monitoring Board in a subsequent full clinical trial.
The EmPeeRie group consists of members with lived 
experience of mental illness, with multiple members 
having lived experience of psychosis and voice hearing. 
The EmPeeRie Project has been accumulating experi-
ence in initiating research projects based on the ideas 
of people with lived experience and in consulting 
researchers in clinical trials since its founding in 2017. 
Members of EmPeeRie receive continuing education as 
part of the group’s training programme for people with 
lived experience.
The current issues of the trial will be presented at the 
regular EmPeeRie group meetings on at least a yearly basis 
during the course of the study to consult on participant 
well- being, accessibility of study materials, recruitment 
and retention, and the interpretation of findings and 
dissemination. The ‘involvement log’ for each consulta-
tion will track the influence of the advice offered to the 
research team by EmPeeRie.
Study setting
Participants will be recruited in four sites: (1) Psychother-
apeutische Hochschulambulanz der Universität Hamburg 
(psychology outpatient clinic at Universität Hamburg), 
(2) Klinik und Poliklinik für Psychiatrie und Psycho-
therapie Universitätsklinikum Hamburg Eppendorf 
(Psychiatric Clinic of the university clinic in Hamburg), 
(3) Christoph- Dornier- Stiftung für Klinische Psychologie 
Bremen (psychology outpatient clinic in Bremen in 
cooperation with Ameos Klinikum Bremen), (4) Psycho-
therapeutische Hochschulambulanz am Institut für 
Psychologie der Universität Leipzig (psychology outpa-
tient clinic at Universität Leipzig).
Eligibility criteria
Patients included in the trial will:
1. have a diagnosis of a schizophrenia spectrum disorder 
(International Classification of Diseases, 10th Revision, 
F2, confirmed by the Structured Clinical Interview for 
Diagnostic and Statistical Manual of Mental Disorders, 
Fifth Edition (DSM-5)); 32
2. be reporting distressing AVH for at least 6 months (to 
be beyond the startle and adjustment phases) and 
score ≥3 on at least one item of the distress factor of 
the PSYRATS- AVH; 30 31
3. be ≥16 and ≤99 years of age;
4. be able to understand the full implications of their 
decision by the responsible psychiatrist or clinical 
psychologist.
Patients are excluded from the trial, if they:
1. have AVH with a clear organic cause (eg, brain disease 
or injury);
2. have exclusively hypnagogic or hypnopompic AVH;
3. have a diagnosis of acute substance dependence 
(F1x.2).
4. have received CBT for psychotic symptoms during the 
past year within which distressing AVHs have been tar-
geted;
5. are currently participating, or be confirmed to par-
ticipate in another interventional study in which they 
are receiving an intervention which uses psychological 
therapy;
6. are non- German speaking to the degree that they are 
unable to fully understand and answer assessment 
questions or give informed consent;
7. are at immediate and serious risk to self or other
Who will take informed consent?
Once a formal referral has been received by the research 
team, the potential participant will be contacted to discuss 
the study further and arrange a consent and eligibility 
meeting with a member of the research team. The poten-
tial participant will have a copy of the patient information 
sheet at least 24 hours before the consent and eligibility 
meeting takes place, so they will have time to read the 
information, discuss it with friends and family, and formu-
late any questions they may have.
Interventions
Explanation for the choice of comparators
A two- arm RCT was chosen to enable: (1) any effect of RT 
to be differentiated from TAU; and (2) to test whether 
adding an RT module to the treatment of patients with 
psychosis and distressing AVHs is superior to TAU alone 
in reducing AVH- related distress.




RT for AVH is a symptom- specific behaviourally oriented 
intervention that targets interpersonal relating as a key 
mechanism associated with AVH distress.29 The aim is 
that patients learn to relate more assertively within the 
difficult relationships they have with both the AVH and 
other people. The RT module will follow a treatment 
manual consisting of three phases:
Phase 1: Socialisation to RT and its implications for 
the inter- relating between the hearer and AVH. Guided 
discussions will explore relationships in terms of power 
and proximity, with reference to participant’s experi-
ences of relating to other people and AVH. Typical ways 
of responding to negative relating (giving in, fighting 
back and trying to escape) are considered and the possi-
bility of relating differently to AVH is introduced.
Phase 2:Exploration of themes within the relational 
history of the participant and their experience of rela-
tionships with AVH, and interpersonal relating within the 
family and social environment (identifying any promi-
nent themes, such as abuse, disempowerment or rivalry). 
Connections are developed across all forms of relating, 
generating a formulation that links past and present 
forms of relating.
Phase 3:Exploration and development of assertive 
approaches to relating to AVH and other people. A 
difficult relationship is chosen to be the initial focus of 
intervention and a specific conversation is explored 
with respect to the participant’s response (identifying 
responses as passive or aggressive). Assertive responses 
are generated as an alternative and experiential role- 
plays are used extensively to practice relating in an asser-
tive manner (including the taking of different roles and 
perspectives within the role- plays). Different relationships 
can be explored in response to need and between- session 
experiences.
Following the procedure in the pilot trial,29 the treat-
ment will take place in individual 50- minute sessions, 
weekly, within a maximum of 16 sessions over a 20- week 
period. This compares with the current National Institute 
for Health and Care Excellence20 guideline recommen-
dation to offer a minimum of 16 sessions of CBTp, and is 
supported by a process analysis of dose×outcome in CBTp 
within the German healthcare setting that found signif-
icant reduction of symptom- related distress to occur by 
session 15 and to remain stable thereafter.33 Therapists 
will be clinical psychologists or psychiatrists enrolled in or 
with completed clinical training, trained and supervised 
by Dr. Hayward (MH).
Participants in the RT condition will continue to receive 
their usual treatment throughout their participation in 
the study.
Treatment as usual
TAU will include medication management, supportive 
brief counselling sessions and various types of psycho-
social support (eg, social work guided support, peer 
support) and monitoring provided by mental health 
services, with individual and family psychological thera-
pies offered occasionally. In recognition of the likelihood 
of TAU being heterogeneous across centres, the type and 
extent of any treatment received will be protocolled at 5 
months (T1) and T2. TAU will be rated in terms of hours 
of therapist time spent with patient. Within a future defin-
itive RCT, this will allow us to: (1) standardise TAU by 
providing all referrers with a manual for standard treat-
ment which summarises good practice; and (2) factor the 
variation into the design and data analysis plan.
Strategies to improve adherence to interventions
Therapeutic drift and contamination will be minimised 
by the use of highly detailed therapy protocols, inten-
sive training of therapists and close supervision based 
on systematic adherence checks of the trial therapists. In 
addition, prior to the trial recruitment, therapists were 
encouraged to deliver RT to pilot cases. MH supervised 
these cases throughout the therapist training and invited 
the therapists to provide feedback on the acceptability of 
delivering RT from a practitioner’s perspective. Feedback 
was generally indicative of high acceptance on the thera-
pists’ side. Emerging questions regarding RT techniques 
or special cases were resolved by discussion with MH. All 
therapy sessions will be audio- recorded (with the partic-
ipant’s permission) and two recordings per participant 
will be randomly drawn by the trial manager for subse-
quent adherence checks. Adherence of trial therapists’ 
delivery of RT will be assessed by MH using an adapted 
version of the Cognitive Therapy Scale for Psychosis 
(CTS- psy).34 Items F, G and H have been changed to 
reflect RT (eg, ‘focus on the link between cognition 
and affect’ was replaced with ‘focus on the effects of the 
patient engaging in different patterns of relating’). The 
full CTS- psy with the adapted items can be found in the 
online supplemental file 1 of this article.
Outcomes
Primary outcome
The change in AVH distress is the primary outcome as 
distress has been prioritised by patients35 and is relevant 
to functioning.11 12 The change in the distress factor score 
of the PSYRATS- AVH30 31 from baseline assessment (T0) 
to the follow- up assessment (T2) will be evaluated as 
candidate for the primary outcome to be used in a future 
definitive RCT.
Secondary outcomes
Secondary outcomes will evaluate: (1) the change from 
baseline to T2 in time spent in social and goal- directed 
activities measured with the Time Budget Measure36 
(2) in health- related quality of life measured with the 
EuroQol Quality of Life Scale (EQ- 5D- 5L),37 in negative 
relating to voices and social others measured with the 
Voice and You questionnaire (VAY)24 and APPROVE 
questionnaires,38 depressive symptoms (Patient 
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Health Questionnaire-9),39 AVH frequency (PSYRATS- 
Frequency)30 31 and the number of rehospitalisations as 
well as all outcomes at T1.
Feasibility outcomes
The assessment of feasibility will include the calculation 
of: number of patients referred within each site, number 
of self- referrals within each site, number of referred 
patients within each site found to be eligible, number 
and proportion of consenting and eligible participants 
who attend 5- month (T1) and 9- month (T2) assessments 
within each site, number and proportion of consenting 
participants within the RT condition who reach the point 
of therapy ‘exposure’ (attended at least 8 of 16 therapy 
sessions), completeness of data collected, therapist adher-
ence to therapy protocols and supervision protocols, and 
the number of adverse (AEs) and serious adverse events 
(SAEs).
Participant timeline
Participant flow through the study is depicted in figure 1 
and will be reported in line with the Consolidated Stan-
dards of Reporting Trials40 2010 statement—extension to 
randomised pilot and feasibility trials.41
Sample size
The sample size calculation is based on the primary 
endpoint, the distress factor score of the PSYRATS- AVH30 31 
at T2 adjusted for the baseline value, in the ITT (intent- to- 
treat) population including all randomised patients. The 
aim is to show that the intervention group is superior to 
the control meaning that the mean score at T2 adjusted 
for baseline is lower in the intervention group than in the 
control group. Sample size calculation is based on a two- 
sample t- test. Since the two- sample t- test ignores the influ-
ence of different baseline values, the baseline- adjusted 
analysis of covariance (ANCOVA) model will yield to an 
increase of statistical power. This strategy for sample size 
calculation defines a conservative procedure.
Hayward et al29 reported observed mean values of 15.7 
and 16.7 at baseline and values of 11.3 and 15.8 at 5- month 
follow- up for intervention and control, respectively, 
resulting in an estimated treatment effect of 15.7–11.3−
(16.7–15.8)=3.5. For the purpose of this feasibility study, 
we assume that the treatment effect will be slightly larger 
at 4.0, which was confirmed as meaningful by people with 
lived experience. The reported SDs in Hayward et al29 at 
5- month follow- up were 5.7 for intervention and 4.9 for 
control, respectively. We therefore conservatively assume 
an SD of 7.0 resulting in a standardised treatment effect 
of 4/(5×√2)=0.57. The required sample size to find a 
significant effect with a power of 0.7 at a two- sided signifi-
cance level of 0.1 is given by 60 patients (30 per treatment 
arm) calculated with the software ADDPLAN, V.6.1. To 
account for approximately 20% drop- out (as motivated 
by the pilot study29 and the COMMAND trial),22 the total 
number of patients to be recruited is 75 (60/75=0.80).
Recruitment
Participants will be recruited through referrals from:
1. clinical practitioners (social workers, psychologists, 
nursing staff, doctors) with contact to patients with 
psychosis in the host cities (and sites).
2. clinical psychologists and psychiatrists in private prac-
tice.
3. practitioners in outpatient and inpatients settings (psy-
chiatric clinics, outpatient counselling services) who 
will be provided with information about the study be-
fore the start of the recruiting period.
Assignment of interventions: allocation sequence generation 
and concealment mechanism
Participants will be randomly allocated using the sealed 
envelope online service ‘simple+’ randomisation by 
https://www. sealedenvelope. com/.
The clinical trials unit statistician will set up and test the 
randomisation procedure using random block lengths. 
Participants will be randomly allocated based on a 1:1 
allocation to receive either the study intervention and 
TAU (RT+TAU) or TAU. Treatment allocation will be 
stratified by site.
Following the set- up of the randomisation procedure, 
automatised allocation will be performed remotely via a 
Figure 1 Illustration of the participant flow through the 
study. RT, Relating Therapy; TAU, treatment as usual.
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website by the on- site contact as soon as inclusion criteria 
have been verified. The full list of participants (anony-
mised participant codes) and allocated treatment will 
be saved at https://www. sealedenvelope. com/ for the 
duration of the trial. Direct access to the randomisation 
protocol and full participant randomisation list is limited 
to the trials unit statistician.
Implementation
Trial therapists will be notified by the trial manager about 
the participants’ allocation and will be asked to arrange a 
first appointment, if possible, within 1 week following the 
randomisation. A letter will be sent to all participants to 
confirm their allocation and details of their next appoint-
ment with the trial.
Assignment of interventions: blinding
Who will be blinded?
Members of the research team and raters will not need to 
be blinded while collecting eligibility and baseline data as 
participants will be randomised after baseline data have 
been collected. Following the eligibility and baseline 
assessment, participants will be allocated to a group and 
raters will be blinded to the allocation and will remain 
blinded for all future assessments with the participants 
(5- month and 9- month assessments). The participant’s 
therapist will be notified of the participant’s group allo-
cation and asked to not discuss this allocation with site 
raters. Participants will be reminded at the beginning of 
each assessment interview to not disclose the group to 
which they have been allocated. Raters will be shielded 
from discussion of participants in forums where the 
possibility of determining the allocation group of the 
participant could occur. The trial manager will manage 
an electronic system to ensure that raters will not access 
information in the database that would reveal the alloca-
tion group.
To further minimise the risks of unblinding, every 
attempt will be made to recruit the raters from within 
different settings so that they do not share offices and/or 
attend the same meetings as therapists, where unblinding 
may occur. If raters are from the same clinical setting as 
therapists, consideration will be given to office allocation 
of blinded versus unblinded members of the research 
team, and the research team must be conscientious when 
making phone calls to participants. ‘Blinding’ awareness 
and education will be promoted throughout the study, 
communicating to administrative staff and referrers the 
importance of the raters remaining blinded to minimise 
the occurrence of accidental blind breaks.
The blind assessor will be asked to record any breaks 
of blinding, even if the break is equivocal. In any of these 
cases, the assessor will be asked to guess the allocation 
group for the respective participant.
Reported breaks in blinding of raters will follow a stan-
dard operating procedure to maintain blind outcome 
assessments by reallocating ‘blind’ raters to collect and 
score study data, therefore not biasing results.
Procedure for unblinding if needed
Reported breaks in blinding will be recorded. The audio 
files of the outcome assessments will be used for a second 
rating by another ‘blind’ rater.
As the therapists will be unblinded, no emergency 
unblinding procedures are required for this study.
Data collection
Trial procedures and evaluations
See table 1 for details of the assessment schedule.
Description of instruments
Screening and eligibility measures
The assessment of eligibility in relation to the inclusion 
and exclusion criteria will be supported by the use of the 
Structured Clinical Interview for DSM-5,42 the distress 
factor of PSYRATS- AVH30 31 and the Columbia Suicide 
Severity Rating Scale.43
Clinical measures—primary
PSYRATS- AVH distress factor score.30 The PSYRATS- AVH 
is a reliable and valid44 11- item rating scale designed to 
measure the severity of different dimensions of the voice 
hearing experience. Items are grouped together in four 
factors45: distress (five items on negative content, distress 
and control); frequency (two items: frequency, duration 
and disruption); attribution (two items: location and 
origin of voices); and loudness (loudness item only). The 
‘distress’ subscale measures the impact that voices have 
on the individual.
Clinical measures—secondary
The Time Budget Measure36 will be used as a highly indi-
vidualised record of activity of the week. The measure 
consists of a week- long diary of activity, in four time 
periods for each day completed retrospectively during a 
structured interview with participants. Interviewers probe 
for activities, degree of independence in activities, and 
number or nature of social contacts. Each activity period 
is rated according to complexity and effort. The measure 
has demonstrated good inter- rater reliability and validity.
The EQ- 5D- 5L37 will be used to assess health- related 
quality of life. The EQ- 5D- 5L37 is a descriptive system and 
visual analogue scale with the endpoints labelled ‘best 
imaginable health state’ and ‘worst imaginable health 
state’. The descriptive system comprises the dimensions 
of mobility, self- care, usual activities, pain/discomfort 
and anxiety/depression and is used for estimating pref-
erence weight for that health status. By combining the 
weight with time, quality- adjusted life years (QALYs) 
can be computed. QALYs gained will then be used as an 
outcome in an additional cost–utility analysis in the subse-
quent full clinical trial. EQ- 5D- 5L37 is one of the most 
commonly used generic health status measurements, 
and its good validity and reliability have been reported in 
various health conditions.
Negative relating between hearer and AVH will be 
assessed with the brief version of the VAY,24 a 14- item 
measure of inter- relating between the hearer and their 
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predominant AVH. Relating is measured across four 
scales: two concerning the hearer’s perception of AVH 
dominance and AVH intrusiveness, and two concerning 
hearer distance and hearer dependence. The VAY24 has 
good internal consistency and acceptable test–retest reli-
ability. Sufficient fit for the brief 14- item version has been 
found in an English sample. The psychometric properties 
of the German version are currently being tested by the 
group of the coordinating investigator in collaboration 
with the authors of the original scale.
The APPROVE questionnaires38 will be used to assess 
dysfunctional as well as functional relating. The APPROVE 
questionnaires38 include two parallel 15- item versions to 
assess relating to AVH and to other people in difficult 
situations. Within each version, two subscaless assess the 
putatively dysfunctional relating styles of passive relating 
and aggressive relating, whereas a third subscale assesses 
functional assertive relating. The APPROVE question-
naires38 have been developed as a diagnostic tool for RT 
in a collaboration project by the group of the therapist 
supervisor and the group of the coordinating investigator. 
They have been found to be reliable and valid in both 
their English and German versions, with the German vali-
dation study currently in preparation for publication.
Additional assessments
A structured post- therapy and follow- up interview will also 
assess the types of intervention a participant has received 
in the period of interest (eg, during the intervention 
period, during the follow- up period) and time spent with 
a therapist in hours. It will also include an assessment of 
frequency and duration of rehospitalisation (which is a 
secondary outcome). Furthermore, it will assess major 
events during the intervention and follow- up periods 
using the questions included in the Netherlands Mental 
Health Survey and Incidence Study.46 Finally, it will assess 
any changes in medication during the intervention/TAU 
or follow- up periods.
Sociodemographic questionnaire and clinical informa-
tion: this instrument includes sociodemographic ques-
tions, such as age, gender, living situation and marital 
status, as well as questions about the medical–psychiatric 
history of the participants.
Plans to promote participant retention and complete follow-up
Efforts will be made to engage all participants in follow- up 
assessments. Research assistants will support the raters to 
flexibly engage patients, offering appointments at times 
and locations which best suit the participants’ schedule 
and offering shorter and split assessment sessions as 
needed. Participants will be offered reimbursement of 
€12 per hour of assessment and travel expenses will be 
made available. Retention rates will be monitored by the 
trial manager at least weekly and by the research team on 
a monthly basis throughout the trial.
Data management
The trial manager will manage the day- to- day data collec-
tion; the clinical trials unit statistician will have over-
sight of the process and provide guidance. All data will 
be collected by trained trial raters (or other appropriate 







SCID-5- CV48 affective disorders, psychotic disorders and substance 
section
x       
Sociodemographic questionnaire and clinical information (20 min) x       
Distress factor of AVH subscale of PSYRATS30 31 (5 items, 5 min) x x x x
C- SSRS43 (10 items, 10 min) x       
Functioning: Time Budget Measure36 (20 min)   x x x
Quality of life: EQ- 5D- 5L37 (self- report, 5 min)   x x x
PSYRATS- AVH30 31 (6 itemsa, 6 min)   x x x
Depression: PHQ-939 (self- report, 9 min)   x x x
Brief version of VAY24 (self- report, 14 items) (5 min)   x x x
APPROVE38 (self- report, 2×15 items) (10 min)   x x x
Post- therapy and follow- up interview standardised protocol to assess TAU 
interventions and rehospitalisation (20 min)
    x x
Cognitive Therapy Scale34—revised   Continuous monitoring and assessment
Adverse events (AEs); serious AEs; changes in medication   Continuous monitoring and assessment
AVH, auditory verbal hallucination; C- SSRS, Columbia Suicide Severity Rating Scale; EQ- 5D- 5L, EuroQol Quality of Life Scale; PHQ-9, Patient Health 
Questionnaire; PSYRATS, Psychotic Symptoms Rating Scale; PSYRATS- AVH, Psychotic Symptoms Rating Scale - Auditory Verbal Hallucinations 
subscale; SCID-5- CV, Structured Clinical Interview for DSM 5 - Clinician Version; TAU, treatment as usual; VAY, Voice and You questionnaire.
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members of the research team) who will be supervised 
by the trial manager and the leads of the respective sites.
All of those involved in the collection and management 
of data will be given training on how to use and admin-
ister the clinical and health economic measures used in 
this study. A 5- hour training will be delivered by the trial 
manager and will include regular monitoring and super-
vision of the raters.
All members of the research team and any other indi-
viduals from collaborating sites involved in collecting, 
inputting, processing, using and sharing data have 
received information governance training. The manage-
ment of the data will be a standing item on the agenda of 
the weekly meeting of the research team.
The feasibility data analysis will be carried out by the 
clinical trials unit statistician and quality checked by the 
trial statistician.
The quantitative data analysis of the clinical outcomes 
will be carried out by the trial statistician and quality 
checked by the clinical trials unit statistician.
Confidentiality
All of the data collected within the research study will be 
kept confidential and identifiable information will not 
be released outside of the research team. Confidentiality 
will only be broken if participants disclose any informa-
tion that would put themselves or another person at risk. 
The minimum amount of personal information needed 
to conduct the study will be obtained from participants. 
Personal and research data will be stored securely on 
study site premises. Physical data, such as consent forms, 
will be locked in filing cabinets on the study site‘s prem-
ises accessible only to members of the research team. 
Electronic data will be stored securely in password- 
protected or encrypted files on a computer accessible 
only to members of the research team at Universität 
Hamburg. All research data will be fully anonymised and 
will be stored separately to personal data. A link file will 
allow for participant research data to be identified. This 
link file will be a password- protected file accessible only 
by the chief investigator (CI) and the trial manager. This 
file will be securely destroyed following the end of the 
study. Quantitative and qualitative data will be appropri-
ately aggregated in any publications arising from the trial 
to protect participant anonymity during and after the 
trial has ended.
Statistical methods
Statistical methods for primary and secondary outcomes
All clinical outcomes will be summarised using descrip-
tive statistics at pre- randomisation (T0), at 5 months (T1) 
and at 9 months (T2) for each arm (RT+TAU, TAU) of 
the study.
Confirmatory analysis will be conducted based on the 
ITT population, defined on the basis of the ITT principle. 
The aim is to show that the intervention group is superior 
to the control meaning that the mean score at 9 months 
(T2) adjusted for the baseline value (T0) is lower in the 
intervention group (I) than in the control group (C). Let 
µ denote the unknown true mean score values. Then the 
corresponding two- sided test hypotheses are formulated 
as follows:
H0: µ_36W, I=µ_36W,C vs H1: µ_36W, I≠µ_36W,C
An ANCOVA adjusted for baseline score values 
using group allocation and study centre as factors will 
be applied. The global two- sided significance level 
is 0.1. Missing values will be replaced using multiple 
imputation.4
Secondary analyses
A sensitivity analysis to the primary efficacy ANCOVA 
model will be applied with additional covariates/factors 
given by age, gender and diagnosis. Descriptive methods 
will be used for the analysis of the secondary outcomes, 
including the calculation of appropriate summary 
measures of the empirical distribution as well as 90% CIs 
and calculation of descriptive two- sided p values. The 
safety analysis includes calculation of frequencies and 
rates of AEs and SAEs. Additionally, sensitivity analyses 
will be conducted for different populations (per- protocol 
population, patients with complete cases). Furthermore, 
statistical methods are used to assess the quality of data. 
All analyses will be conducted using validated statistical 
software.
Further details will be provided in a statistical analysis 
plan, which will be developed by the Institute of Biometry 
and Clinical Epidemiology, Charité Universitätsmedizin 
Berlin (director: Professor Dr Geraldine Rauch) who will 
be responsible for the data analysis.
OVERSIGHT AND MONITORING
Composition of the Trial Steering Committee
Medical Research Council Guidelines for Management 
of Global Health Trials47 informed the constitution of 
the Trial Steering Committee (TSC), which includes an 
independent chair, independent experts, lay members 
and a person with lived experience, who will provide 
patient and public involvement oversight of the trial.
The scientific integrity including oversight of the safety 
and data integrity of the trial will be overseen by the TSC. 
During the study, the TSC will be asked to consider data 
on SAE and AE, discuss the interim safety analyses, and 
advise the research team on issues related to recruiting 
and on whether to continue, modify or stop the trial 
for reasons related to safety. Ethical considerations have 
been reviewed and approved by the ethics committee of 
the German Psychological Association and by the ethics 
committee of the Medical Board Hamburg.
AE reporting and harms
Any unfavourable and unintended sign, symptom or 
illness that develops or worsens during the period of 
the study will be classified as an AE, whether or not it 
is considered to be related to the study treatment. AEs 
will include: an exacerbation of a pre- existing illness, 
9Lincoln TM, et al. BMJ Open 2021;11:e046390. doi:10.1136/bmjopen-2020-046390
Open access
an increase in the frequency or intensity of a pre- 
existing episodic event or condition; a condition that 
is detected after trial intervention administration; and 
continuous persistent illness or a symptom present at 
baseline that worsens following administration of the 
trial treatment—and may be expected or unexpected. 
SAEs are those considered to be life- threatening, 
resulting in death, requiring inpatient hospitalisation 
or prolongation of existing hospitalisation, resulting 
in significant or persistent incapacity/disability or a 
birth defect or congenital abnormality.
AEs must be recorded by the trial team member noti-
fied of the AE in conjunction with the respective site lead, 
who will check the AE form at the earliest opportunity 
and inform the trial manager within 1 working day.
The trial manager will review the AE and disseminate 
to the CI within 72 hours of being informed to assess 
causality.
In any case of a SAE, the trial manager must be noti-
fied within 1 working day by a member of the trial team 
becoming aware of the event. The trial manager must 
notify the CI within 1 working day after becoming aware 
of the event. The CI (or a clinically qualified delegate) 
will review all SAE reports received. In the event of 
disagreement between the causality assessment given by 
the site lead and the CI, both opinions and any justifica-
tions will be provided in subsequent reports. The CI will 
keep investigators informed of any safety issues that arise 
during the course of the trial. The CI is responsible for 
reporting fatal and life- threatening serious adverse reac-
tions to the competent authorities within 7 days of the CI 
becoming aware of the event. The TSC will be informed 
of serious adverse reactions periodically.
Data sharing
Data sharing will follow the guidelines set up by the 
German Research Foundation and taking into consider-
ations the recommendations set up by the German Psycho-
logical Association (DGPs) in 2016 (https://www. dfg. de/ 
download/ pdf/ foerderung/ antragstellung/ forschungs-
daten/ empfehlungen_ forschungsdaten_ psychologie. 
pdf) . Only anonymised data will be shared outside of 
the research team. A data sharing agreement will be set 
up with individuals who are outside of the research team 
and who request to use the study data. It will be ensured 
that access to the data is still guaranteed when, through 
publication, the rights of use relating to research data are 
transferred to a third party.
The CI can give approval for data sharing requests. The 
possibility of data sharing will be made explicit to partici-
pants on the study consent form.
DISCUSSION
Evidence for the effectiveness of available treatment 
options specifically for distressing voices in the context 
of psychosis is limited. RT is a promising and newly devel-
oped psychological therapy that has been developed from 
the literature and explores the experience of hearing 
voices within interpersonal frameworks. RT aims to 
rebalance the hearer–voice relationship and other diffi-
cult relationships through the development of assertive 
responding and has been found to be safe, acceptable, 
and intuitively appealing to therapists and hearers within 
an initial pilot trial. This larger multicentre pilot RCT 
will generate a refined study protocol, an indication of 
recruitment and retention rates, and an estimate of the 
effect size, in order to inform the sample size calculation 
for a future definitive RCT within the German healthcare 
system. If evidence from a definitive RCT suggests that 
RT is effective, this will extend the range of evidence- 
based psychological therapies available to patients with 
psychosis who hear distressing voices.
TRIAL STATUS
Recruitment to the trial commenced in October 2020 
(study protocol—V.1.2, dated 24 September 2020) and is 
planned to finish in June 2022. Data collection is planned 
to continue until March 2023.
ETHICS AND DISSEMINATION
The study received ethical approval by the ethics 
committee of the German Psychological Society (refer-
ence number: LincolnTania2020-03- 19VADM). Partici-
pants will provide written informed consent prior to the 
completion of any study procedures. The sponsor played 
no part in study design; collection, management, analysis, 
and interpretation of data; writing of the report; and the 
decision to submit the report for publication.
Trial findings will be disseminated in open- access publi-
cation in high- impact scientific publications, including 
feasibility outcomes. Findings will be disseminated to 
participants’ and patient organisations. Research team 
members will participate in dissemination including 
use of social media to disseminate findings, producing 
leaflets for wide distribution and submitting a summary 
of findings to a non- academic journal. Findings will be 
presented at patient events and at local, national and 
international conferences.
Twitter Mark Hayward @sussexvoices
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